Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Q1 2026 · $51.0MThe company’s own SEC segment disclosure.
- Zusduri$29.2M57%
- Jelmyto$21.7M43%
UroGen Pharma Ltd. (URGN) reported revenue of $51M in Q1 2026 (quarter ended March 31, 2026), up 152% from the same quarter a year earlier. That came with a gross margin of 92% and net loss of $24M. For the full year FY2025, revenue was $110M (+21% year on year) and net income −$153M. Its largest product in 2026-Q1 was Zusduri at $29M, 57% of the disclosed total, just ahead of Jelmyto at 43%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.